A5010902289- Genetic factors in colorectal cancer
- Pancreatic and Hepatic Oncology Research
- Colorectal Cancer Treatments and Studies
- Gastric Cancer Management and Outcomes
- Cancer Genomics and Diagnostics
- Gastrointestinal Tumor Research and Treatment
- Colorectal and Anal Carcinomas
- Colorectal Cancer Surgical Treatments
- Inflammatory Bowel Disease
- Gastrointestinal disorders and treatments
- Cancer Immunotherapy and Biomarkers
- Colorectal Cancer Screening and Detection
- Cholangiocarcinoma and Gallbladder Cancer Studies
- Neuroendocrine Tumor Research Advances
- Microscopic Colitis
- Autoimmune and Inflammatory Disorders
- Intraperitoneal and Appendiceal Malignancies
- Esophageal Cancer Research and Treatment
- Radiomics and Machine Learning in Medical Imaging
- Hedgehog Signaling Pathway Studies
- Helicobacter pylori-related gastroenterology studies
- Ovarian cancer diagnosis and treatment
- Metastasis and carcinoma case studies
- Epigenetics and DNA Methylation
- Diverticular Disease and Complications
Sorbonne Université
2016-2025
Assistance Publique – Hôpitaux de Paris
2016-2025
Laboratoire d'Informatique Médicale et d'Ingénierie des Connaissances en e-Santé
2025
Hôpital Saint-Antoine
2015-2024
Centre de Recherche Saint-Antoine
2012-2024
Sorbonne Paris Cité
2020-2023
Inserm
2006-2022
John Wiley & Sons (United States)
2021
GERCOR (France)
2020-2021
Hudson Institute
2021
Purpose Nivolumab provides clinical benefit (objective response rate [ORR], 31%; 95% CI, 20.8 to 42.9; disease control rate, 69%; 12-month overall survival [OS], 73%) in previously treated patients with DNA mismatch repair-deficient (dMMR)/microsatellite instability-high (MSI-H) metastatic colorectal cancer (mCRC); nivolumab plus ipilimumab may improve these outcomes. Efficacy and safety results for the cohort of CheckMate-142, largest single-study report an immunotherapy combination...
In patients with resectable gastric/gastroesophageal junction (GEJ) adenocarcinoma, surgery plus perioperative platinum-based chemotherapy is the standard of care. Perioperative remains debatable for gastric/GEJ adenocarcinoma deficient mismatch repair (dMMR)/microsatellite instability-high (MSI-H).NEONIPIGA (ClinicalTrials.gov identifier: NCT04006262) phase II study evaluated neoadjuvant nivolumab 240 mg once every two weeks ×6 and ipilimumab 1 mg/kg six ×2, followed by adjuvant 480 four...
Abstract Currently, the main targets of drug therapy for ulcerative colitis [UC] are endoscopic and clinical remission. However, there is active discussion about additional advantages including histological remission as a target. Accumulating evidence indicates that microscopic activity persists in endoscopically quiescent UC, changes may lag behind after treatment, absence predicts lower rates relapse, hospitalization, surgery subsequent neoplasia. Obtaining useful information from mucosal...
Despite unprecedented benefit from immune checkpoint inhibitors (ICIs) in patients with mismatch repair deficient (dMMR)/microsatellite instability high (MSI-H) advanced gastrointestinal cancers, a relevant proportion of shows primary resistance or short-term disease control. Since malignant effusions represent an immune-suppressed niche, we investigated whether peritoneal involvement without ascites is poor prognostic factor dMMR/MSI-H metastatic colorectal cancer (mCRC) and gastric (mGC)...
Abstract Background The significance of positive para-aortic nodes in patients with resectable pancreatic carcinoma is unclear. This study sought to evaluate the accuracy intraoperative detection and prognostic these lymph resected adenocarcinoma head. Methods From 2000 2010, node sampling was performed prospectively all before pancreatoduodenectomy. Frozen sections were created categorized as or negative for metastases. Surgeons blinded frozen-section results. followed by standard...
Background The magnitude and drivers of the risk serious viral infections in Inflammatory Bowel diseases (IBD) are unclear. Objective objective this study was to assess incidence factors for systemic IBD patients. Methods Using MICISTA, a database detailing prospective characteristics complications IBD, we identified patients that were followed 2005–2014 outside context organ transplantation, HIV infection or chronic hepatitis. We estimated incidences infections, defined by need...
Abstract Missense mutations in the polymerase epsilon (POLE) gene have been reported to generate proofreading defects resulting an ultramutated genome and sensitize tumors checkpoint blockade immunotherapy. However, many POLE-mutated do not respond such treatment. To better understand link between POLE mutation variants response immunotherapy, we prospectively assessed efficacy of nivolumab a multicenter clinical trial patients bearing advanced mismatch repair–proficient solid tumors. We...
244 Background: In pts with resectable gastric adenocarcinoma or OGA, radical surgery is the only curative option and perioperative chemotherapy seems worthless for those MSI/dMMR tumors. Methods: We conducted phase II study evaluating efficacy of neo-adjuvant nivolumab ipilimumab followed by adjuvant in MSI/dMMR, T2-T4 NxM0 Treatment consisted 240 mg every 2 weeks (6 infusions) 1 mg/kg 6 (2 infusions), 5 (±1 week) after last injection nivolumab. Pts Becker tumor regression grade (TRG) <...
In inflammatory bowel disease [IBD], mucosal healing is a major therapeutic target and reliable predictor of clinical course. However, endoscopic not synonymous with histological healing, the additional benefits including remission as are unclear. Crohn´s [CD], there few studies highlighting value target. Histological activity can persist in CD patients who remission, absence may be associated lower relapse rates. Therefore, standardisation procedures to evaluate desirable. Topics that would...
Mismatch Repair Deficiency (dMMR)/Microsatellite Instability (MSI) is a key biomarker in colorectal cancer (CRC). Universal screening of CRC patients for MSI status now recommended, but contributes to increased workload pathologists and delayed therapeutic decisions. Deep learning has the potential ease dMMR/MSI testing accelerate oncologist decision making clinical practice, yet no comprehensive validation clinically approved tool been conducted. We developed MSIntuit, artificial...
Two tumor (Classical/Basal) and stroma (Inactive/active) subtypes of Pancreatic adenocarcinoma (PDAC) with prognostic theragnostic implications have been described. These molecular were defined by RNAseq, a costly technique sensitive to sample quality cellularity, not used in routine practice. To allow rapid PDAC subtyping study heterogeneity, we develop PACpAInt, multi-step deep learning model. PACpAInt is trained on multicentric cohort (n = 202) validated 4 independent cohorts including...
Abstract Histological assessment of endoscopic biopsies in inflammatory bowel disease [IBD] plays an important role clinical management, investigative studies, and trials. Scoring schemes consisting multiple histological items offering considerable precision are widely available. However, definitions abnormalities often inconsistent. Furthermore, interobserver variability for their recognition may be high. The European Crohn’s Colitis Organisation [ECCO] formed expert panel to explore IBD,...
Chronic inflammation and cancer are intimately associated. This is particularly true for inflammatory bowel diseases (IBD), such as ulcerative colitis Crohn's disease, which show a major increased risk colorectal cancer. While the understanding of molecular pathogenesis IBD has recently improved, mechanisms that link these chronic states to development in large part unknown. One NF-κB pathway activation turn may contribute tumor formation by providing anti-apoptotic survival signals...
Objectives Asparaginase encapsulated in erythrocytes (ERY-ASP) is a potentially effective drug patients with pancreatic adenocarcinoma (PAC) null/low asparagine synthetase (ASNS) expression. Our aims were to assess ASNS expression PAC from large cohort and its prognostic and/or predictive value conduct phase I trial ERY-ASP metastatic PAC. Methods Asparagine was evaluated using immunohistochemistry resected (471 patients) pairs of primary tumor metastases (55 patients). Twelve included the...
// Benjamin Le Calvé 1, 2, 3, 4, 14 , Audrey Griveau * David Vindrieux Raphaël Maréchal 5 Clotilde Wiel 4 Magali Svrcek 6, 7 Johann Gout Lamia Azzi 8 Léa Payen 9 Jérôme Cros 10, 11 Christelle de la Fouchardière 3 Pierre Dubus Guitton Laurent Bartholin Jean-Baptiste Bachet 12, 13 Bernard 1 Inserm U1052, Centre Recherche en Cancérologie Lyon, France 2 CNRS UMR5286, Léon Bérard, Université Department of Gastroenterology and Gastrointestinal Cancer Unit, Erasme Hospital, Libre Bruxelles, Belgium...